UNSPSC 51144004: Azalanstat dihydrochloride

This classification denotes an anti-lipidemic agent with the molecular formula C22H24ClN3O2S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X30J960B4D, chemically known as 1-(((2s,4s)-4-(((p-aminophenyl)thio)methyl)-2-(p-chlorophenethyl)-1,3-dioxolan-2-yl)methyl)imidazole but more generally known as azalanstat dihydrochloride, which bears US NIH Compound Identifier 60876. Most nations, for tariff and trade purposes, schedule azalanstat dihydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, AZALANSTAT DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Azalanstat dihydrochloride bears US NLM identifiers UMLS ID C2698284 and NCI Concept Code C80126. SMILES: C1CC(CCC1CC[C@@]2(OC[C@H](O2)CSC3CCC(CC3)N)CN4CCNC4)CL.CL.CL.

UNSPSC 51144004 Azalanstat dihydrochloride is a Commodity code that shows minimal alignment with actual state and local procurement activity. The code nominally describes a specific pharmaceutical compound, but recent state and local solicitations tagged under this code are acquiring naloxone, multi-source generic pharmaceuticals, OTC products, and direct-to-manufacturer prescription programs—none of which are azalanstat dihydrochloride. The mismatch suggests either tagging error in the source system or that the code is not actively used for its intended scope in state and local procurement. Across the recent opportunities, issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance covering Minnesota and Oregon). The work involves procurement of pharmaceutical products for community health initiatives, state employee and retiree health plans, and distributed government facilities.

Geographic activity centers on Florida, Texas, Minnesota, and Oregon based on recent solicitations. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs serving state employee health plans. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, and contract effectiveness of July 1, 2026. The code shows little relevant recent activity and does not track active procurement of azalanstat dihydrochloride in state and local markets based on available opportunities.